Crescendo Bioscience, Inc. (NASDAQ:MYGN)

CAPS Rating: 3 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Recs

0
Player Avatar pchop123 (79.55) Submitted: 2/26/2013 11:26:53 AM : Outperform Start Price: $25.00 MYGN Score: -6.10

oversold

Featured Broker Partners


Advertisement